Did You Ask Yourself :
How does Santa Remember Every Kid?
What is Choline ? Benefits , Sources and Signs of Deficiency
Today life moves on faster than ever before! Jobs are more exhausting, tiresome and demanding.
Did you ever feel overwhelmed by your daily tasks? Did you feel that you need to be more focused on what you have to do? Or do you simply experience symptoms of impaired memory or mental fatigue?
If the answer is yes, this article is for you, it will help you take the right decision which will help you get in the mental shape that you want!
In order to keep up with the hectic schedule that we have every day, we have to sustain it with quality nutrients and vitamins.
Alpha-GPC, also known as alpha-glycerophosphocholine or choline alfoscerate, is a choline compound that occurs naturally in the human brain. Supplementation with Alpha-GPC provides both improvement and geroprotective effects, supporting healthy cognitive function as the brain ages, according to these clinical studies on humans published after scientific studies.
- Efficacy and tolerability of choline in patients with Parkinson's and Cognitive desease.
In 2009, this study found that marked and moderate improvement of cognitive functions was found in patients of the Alpha-GPC group compared to the control one. Deterioration of cognitive functions was seen less often in the group that used Alpha GPC supplementation than in the control group.
- Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine.
In 2003, this study found that clinical usefulness and tolerability of Alpha-GPC in the treatment of the cognitive symptoms of dementia disorders of the Alzheimer type.
- Alpha-Glycerophosphocholine in the mental recovery of induviduals in cerebral decline
In 1994, this trial confirmed that the therapeutic role of alpha-GPC on the cognitive recovery of patients with acute stroke or TIA, and the low percentage of adverse events confirms its excellent tolerability.
- Multicentre study of Alpha-GPC vs ST200 among patients with probable senile Dementia of Alzheimer's.
In 1993, this study found significant improvements in most neuropsychological parameters in the alpha GPC recipients.
- A neurotropic approach to the treatment of multi-infarct dementia using A-GPC
In 1992, this study found that patients receiving L-α-GPC showed a significant improvement of cognitive functions, behavior, and personality at the end of the treatment.
- Nootropic therapy of cerebral aging.
In 1991, this study found that Alpha-GPC was well tolerated and can be expected to be highly effective in long-term patient management.
- A multicentre trial to evaluate the efficacy and tolerability of Alpha GPC in patients with Dementia.
In 1991, this study found that Alpha-GPC produced a definite cognitive improvement and showed a very good tolerability.
These clinical study reviews confirm that supplementation of Alpha-GPC supports healthy brain functions even in cases of Dementia and Alzheimer
Do You Need To Be Highly Focused and Organized At Work?
- Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review.
In 2012, this review states that Alpha-GPC enhances cognitive functioning and is, among several precursors, active in increasing acetylcholine levels in the brain. Therefore, it may represent a therapeutic option to improve the beneficial effects of cholinergic therapy in patients with Alzheimer’s disease and individuals with cognitive decline symptoms.
- Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data.
In 2001, this review found that clear internal consistency of clinical data gathered by different experimental situations on Alpha-GPC effect, especially with regard to the cognitive symptoms (memory, attention) characterising the clinical picture of adult-onset dementia disorders".
Among alternatives Alpha-GPC is the most bioavailable source of choline for the brain. According to these studies, Phosphatidylcholine may be less effective at reaching the brain, and CDP-Choline may be less efficient per dose:
- Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
In 2007, this study found that "lecithin did not show any clear clinical benefit on symptoms of dementia disorders".
- A multicentre trial to evaluate the efficacy and tolerability of alpha-glycerylphosphorylcholine in patients with vascular dementia.
In 1991, this study found that "alpha-GPC possessed a statistical higher efficacy and an overall more satisfactory activity assessed by both patients and investigators compared with CDP".